Parabilis Medicines has closed an oversubscribed $305 million Series F financing to advance its lead cancer drug candidate FOG-001 and expand its Helicon peptide platform. The round was co-led by RA Capital, Fidelity, and Janus Henderson at a higher valuation than the company’s previous financing.
VCXpress